These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1160 related articles for article (PubMed ID: 16583579)
1. Prevalence of prostate cancer in aging males receiving PSA (prostate specific antigen) screening test (A campaign for celebration of Siriraj Established Day). Srinualnad S; Charoenkraikamol C; Toraksa S; Uiprasertkul M; Amornvesukit T; Taweemonkongsap T; Udompunturak S; Nualyong C; Tantiwong A J Med Assoc Thai; 2006 Jan; 89(1):37-42. PubMed ID: 16583579 [TBL] [Abstract][Full Text] [Related]
2. The prevalence of prostate cancer screening in Thai elderly. Tantiwong A; Soontrapa S; Sujijantrarat P; Vanprapar N; Sawangsak L J Med Assoc Thai; 2002 Apr; 85(4):502-8. PubMed ID: 12118499 [TBL] [Abstract][Full Text] [Related]
3. High prevalence of screening-detected prostate cancer among Afro-Caribbeans: the Tobago Prostate Cancer Survey. Bunker CH; Patrick AL; Konety BR; Dhir R; Brufsky AM; Vivas CA; Becich MJ; Trump DL; Kuller LH Cancer Epidemiol Biomarkers Prev; 2002 Aug; 11(8):726-9. PubMed ID: 12163325 [TBL] [Abstract][Full Text] [Related]
4. Lower urinary tract symptoms and risk of prostate cancer in Japanese men. Matsubara A; Yasumoto H; Teishima J; Seki M; Mita K; Hasegawa Y; Yoshino T; Kato M; Usui T Int J Urol; 2006 Aug; 13(8):1098-102. PubMed ID: 16903936 [TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of percent free PSA for prostate cancer detection in men with a total PSA of 4-10 ng/ml. Bermúdez-Tamayo C; Martín Martín JJ; González Mdel P; Pérez Romero C Urol Int; 2007; 79(4):336-44. PubMed ID: 18025853 [TBL] [Abstract][Full Text] [Related]
6. Percent free PSA as an additional measure in a prostate cancer screen. Miele ME Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982 [TBL] [Abstract][Full Text] [Related]
7. Prevalence of prostate specific antigen testing for prostate cancer in elderly men. Dyche DJ; Ness J; West M; Allareddy V; Konety BR J Urol; 2006 Jun; 175(6):2078-82. PubMed ID: 16697807 [TBL] [Abstract][Full Text] [Related]
8. Population-based screening for prostate cancer by measuring total serum prostate-specific antigen in Iran. Hosseini SY; Moharramzadeh M; Ghadian AR; Hooshyar H; Lashay AR; Safarinejad MR Int J Urol; 2007 May; 14(5):406-11. PubMed ID: 17511722 [TBL] [Abstract][Full Text] [Related]
9. [Screening for early detection of prostate cancer (first experience in Israel)]. Neheman A; Shotland Y; Metz Y; Stein A Harefuah; 2001 Jan; 140(1):4-10, 88, 87. PubMed ID: 11242898 [TBL] [Abstract][Full Text] [Related]
10. [Screening of cancer of the prostate: study in a Spanish population]. Herrero Payo JA; Montes Díaz MJ; Páez Borda A; Sánchez Sánchez E; Moreno Valle JA; Berenguer Sánchez A Arch Esp Urol; 1996; 49(6):595-606. PubMed ID: 8929102 [TBL] [Abstract][Full Text] [Related]
11. Prevalence of lower urinary tract symptoms and prostate enlargement in the primary care setting. Naslund MJ; Gilsenan AW; Midkiff KD; Bown A; Wolford ET; Wang J Int J Clin Pract; 2007 Sep; 61(9):1437-45. PubMed ID: 17686091 [TBL] [Abstract][Full Text] [Related]
12. [Prostate-specific antigen in the diagnosis of organ-confined treatable prostate carcinoma]. Recker F Schweiz Med Wochenschr; 1996 Nov; 126(44):1881-90. PubMed ID: 8984601 [TBL] [Abstract][Full Text] [Related]
13. Long term follow-up of mass screening for prostate carcinoma in men with initial prostate specific antigen levels of 4.0 ng/ml or less. Ito K; Kubota Y; Yamamoto T; Suzuki K; Fukabori Y; Kurokawa K; Yamanaka H Cancer; 2001 Feb; 91(4):744-51. PubMed ID: 11241242 [TBL] [Abstract][Full Text] [Related]
14. Contemporary prostate cancer prevalence among T1c biopsy-referred men with a prostate-specific antigen level < or = 4.0 ng per milliliter. Ahyai SA; Graefen M; Steuber T; Haese A; Schlomm T; Walz J; Köllermann J; Briganti A; Zacharias M; Friedrich MG; Karakiewicz PI; Montorsi F; Huland H; Chun FK Eur Urol; 2008 Apr; 53(4):750-7. PubMed ID: 17964070 [TBL] [Abstract][Full Text] [Related]
15. [An experience of individual and early diagnosis of prostate cancer in a Tunisian centre]. Khouaja K; Ben Sorba N; Bouslama A; Youssef A; Taher Mosbah A Prog Urol; 2005 Apr; 15(2):255-9. PubMed ID: 15999603 [TBL] [Abstract][Full Text] [Related]
16. Prostate-specific antigen testing in general practice: a survey among 325 general practitioners in Denmark. Jønler M; Eddy B; Poulsen J Scand J Urol Nephrol; 2005; 39(3):214-8. PubMed ID: 16118092 [TBL] [Abstract][Full Text] [Related]
17. A multicenter study on the detection of prostate cancer by digital rectal examination and prostate-specific antigen in men with or without urinary symptoms. Cooperative Group for Diagnosis of Prostate Cancer. Eur Urol; 1997; 32(2):133-9. PubMed ID: 9286642 [TBL] [Abstract][Full Text] [Related]
18. Diagnosis, management and screening of early localised prostate cancer. Selley S; Donovan J; Faulkner A; Coast J; Gillatt D Health Technol Assess; 1997; 1(2):i, 1-96. PubMed ID: 9414541 [TBL] [Abstract][Full Text] [Related]
19. The role of the digital rectal examination in subsequent screening visits in the European randomized study of screening for prostate cancer (ERSPC), Rotterdam. Gosselaar C; Roobol MJ; Roemeling S; Schröder FH Eur Urol; 2008 Sep; 54(3):581-8. PubMed ID: 18423977 [TBL] [Abstract][Full Text] [Related]
20. Comparative study on the prevalence of clinically detectable prostate cancer in patients with and without bladder cancer. Kurokawa K; Ito K; Yamamoto T; Takechi H; Miyamoto S; Suzuki K; Yamanaka H Urology; 2004 Feb; 63(2):268-72. PubMed ID: 14972469 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]